Literature DB >> 10982503

Prolonged cold ischemia time obviates the benefits of 0 HLA mismatches in renal transplantation.

C M Lee1, J T Carter, E J Alfrey, N L Ascher, J P Roberts, C E Freise.   

Abstract

HYPOTHESIS: Recipients of 0 HLA mismatch kidneys with prolonged cold ischemia times of longer than 36 hours do not have superior outcomes compared with recipients of kidneys with 1 or more mismatches.
DESIGN: Retrospective review.
SETTING: Transplanation centers. PATIENTS AND METHODS: A total of 63,688 recipients who underwent transplantation between January 1, 1990, and July 31, 1998. MAIN OUTCOME MEASURES: Delayed graft function, serum creatinine level, and patient and renal graft survival.
RESULTS: Recipients of 0 HLA mismatch kidneys with fewer than 36 hours of cold ischemia time had better 5-year graft survival (75%) when compared with recipients with 1 or more mismatches (67%) (P<.001). However, recipients of 0 HLA mismatch kidneys with longer than 36 hours of cold ischemia time did not have any graft survival advantage (71% in 0 HLA mismatch kidneys vs 72% in 1 or more mismatches, P =.24).
CONCLUSIONS: Cold ischemia times of longer than 36 hours obviate the benefits of better graft survival conferred by better matching.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10982503     DOI: 10.1001/archsurg.135.9.1016

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  9 in total

1.  Kidney proteome changes provide evidence for a dynamic metabolism and regional redistribution of plasma proteins during torpor-arousal cycles of hibernation.

Authors:  Alkesh Jani; David J Orlicky; Anis Karimpour-Fard; L Elaine Epperson; Rae L Russell; Lawrence E Hunter; Sandra L Martin
Journal:  Physiol Genomics       Date:  2012-05-29       Impact factor: 3.107

Review 2.  How to make better use of thrombolytic therapy in acute ischemic stroke.

Authors:  Geoffrey A Donnan; Stephen M Davis; Mark W Parsons; Henry Ma; Helen M Dewey; David W Howells
Journal:  Nat Rev Neurol       Date:  2011-06-14       Impact factor: 42.937

3.  HLA-DQ Mismatching and Kidney Transplant Outcomes.

Authors:  Napat Leeaphorn; Jeremy Ryan A Pena; Natanong Thamcharoen; Eliyahu V Khankin; Martha Pavlakis; Francesca Cardarelli
Journal:  Clin J Am Soc Nephrol       Date:  2018-04-23       Impact factor: 8.237

4.  Ezrin functionality and hypothermic preservation injury in LLC-PK1 cells.

Authors:  Tao Tian; Susanne L Lindell; Melody Lam; Martin J Mangino
Journal:  Cryobiology       Date:  2012-04-23       Impact factor: 2.487

5.  Long Cold Ischemia Times in Same Hospital Deceased Donor Transplants.

Authors:  Eric K Chow; Sandra DiBrito; Xun Luo; Corey E Wickliffe; Allan B Massie; Jayme E Locke; Sommer E Gentry; Jacqueline Garonzik-Wang; Dorry L Segev
Journal:  Transplantation       Date:  2018-03       Impact factor: 4.939

6.  Optimized outcomes for renal allografts with cold ischemic times of 20 h or greater.

Authors:  Anja Gallinat; Andreas Paul; Thomas Minor; Jürgen W Treckmann; Ernesto P Molmenti; Oliver Witzke; Georgios C Sotiropoulos
Journal:  Int Urol Nephrol       Date:  2012-07-01       Impact factor: 2.370

7.  Significant Improvement in Rat Kidney Cold Storage Using UW Organ Preservation Solution Supplemented With the Immediate-Acting PrC-210 Free Radical Scavenger.

Authors:  Bret M Verhoven; Aos S Karim; Natalie M Bath; Carol J Sarabia Fahl; Nancy A Wilson; Robert R Redfield; William E Fahl
Journal:  Transplant Direct       Date:  2020-07-15

8.  Protective effects of ezrin on cold storage preservation injury in the pig kidney proximal tubular epithelial cell line (LLC-PK1).

Authors:  Tao Tian; Susanne L Lindell; Scott C Henderson; Martin J Mangino
Journal:  Transplantation       Date:  2009-05-27       Impact factor: 4.939

Review 9.  Review: Ischemia Reperfusion Injury-A Translational Perspective in Organ Transplantation.

Authors:  André Renaldo Fernández; Rodrigo Sánchez-Tarjuelo; Paolo Cravedi; Jordi Ochando; Marcos López-Hoyos
Journal:  Int J Mol Sci       Date:  2020-11-13       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.